Back to top
more

Edwards Lifesciences (EW)

(Delayed Data from NYSE)

$87.98 USD

87.98
1,786,623

+0.52 (0.59%)

Updated May 24, 2024 04:00 PM ET

After-Market: $87.97 -0.01 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (144 out of 250)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Henry Schein (HSIC) Q1 Earnings Miss, Operating Margin Dips

Henry Schein's (HSIC) first-quarter results largely reflect lower contributions from the sales of PPE products and COVID-19 test kits.

Omnicell's (OMCL) New Acquisitions Aid Growth, Cost Woes Stay

Omnicell (OMCL) remains well-positioned to meet pharmacy and hospital needs, backed by the recent acquisitions and expansion of its advanced services solutions.

Bruker's (BRKR) New Buyout to Advance Digital Transformation

Bruker's (BRKR) IDS division expands its unique vendor-agnostic software solutions portfolio by integrating ZONTAL with the Mestrelab Research and Arxspan scientific software solutions.

Here's Why You Should Retain Abbott (ABT) Stock For Now

Investors are optimistic about Abbott (ABT) on continued growth in the core Diagnostics arm.

Teleflex (TFX) Q1 Earnings Top Estimates, 2023 Sales View Up

Teleflex (TFX) registers growth across the majority of its businesses, including double-digit increases in interventional and surgical revenues in Q1.

Globus Medical (GMED) Q1 Earnings Beat, Operating Margin Dips

The significant year-over-year surge in Globus Medical's (GMED) Enabling Technologies sales is driven by ongoing demand for the company's robotics and imaging system technologies.

Insulet (PODD) Q1 Earnings Beat Estimates, Sales View Up

Omnipod 5 continues to be a driving force of Insulet's (PODD) strong U.S. growth, representing almost 95% of U.S. new customer starts in the first quarter.

Bruker (BRKR) Tops Q1 Earnings Estimates, Raises '23 Outlook

Bruker (BRKR) delivers a year-over-year revenue increase across all its segments in the first quarter, led by the strong demand for differentiated, high-performance scientific instruments and life-science solutions.

Bio-Rad (BIO) Q1 Earnings Beat Estimates, Operating Margin Down

Bio-Rad's (BIO) first-quarter results reflect core strength across the Life Science and Clinical Diagnostics segments amid ongoing supply-chain constraints.

Amedisys (AMED) Q1 Earnings Beat Estimates, Margins Dip

Amedisys (AMED) sees a year-over-year decline in the Hospice segment's revenues.

Tandem Diabetes (TNDM) Q1 Earnings Miss, Gross Margin Dips

According to Tandem Diabetes (TNDM), Q1 revenues are in line with the high end of its expectations.

OPKO Health (OPK) Q1 Earnings and Revenues Top Estimates

Despite OPKO Health's (OPK) robust RAYALDEE sales and strength in the Pharmaceuticals segment, its overall first-quarter results reflect soft performances.

QuidelOrtho (QDEL) Q1 Earnings Top Estimates, FY23 View Revised

Despite solid performances by the Labs segment and China region, QuidelOrtho (QDEL) reports soft overall top-line results in first-quarter 2023.

Phibro (PAHC) Q3 Earnings Miss Estimates, Gross Margin Up

Higher domestic demand and higher average selling prices for dairy products and growth in the companion animal product drive Phibro's (PAHC) Q3 revenues.

Envista (NVST) Q1 Earnings Miss Estimates, Margins Down

Weakness in China and Russia and lower demand for large capital equipment hurts Envista's (NVST) Q1 revenues.

BD (BDX) Q2 Earnings Surpass Estimates, FY23 View Revised

BD's (BDX) overall top line benefits from revenue growth in the majority of its segments and both geographic regions in the fiscal second quarter.

Cardinal Health (CAH) Beats on Q3 Earnings, Ups '23 EPS View

Cardinal Health's (CAH) fiscal third-quarter results benefit from the Pharmaceutical segment's solid performance.

Qiagen (QGEN) Q1 Earnings Top Estimates, Operating Margin Down

Amid an uncertain macroeconomic environment, Qiagen's (QGEN) first-quarter results reflect an impressive organic top line, led by strength in non-COVID-19 product groups.

Myriad Genetics (MYGN) Lags Q1 Earnings, Updates '23 View

Myriad Genetics (MYGN) delivers a year-over-year increase in first-quarter revenues, reflecting a positive volume improvement across the portfolio.

Inari Medical (NARI) Q1 Earnings Top, Revenues Rise Y/Y

Inari Medical's (NARI) first-quarter results benefit from significant progress made across all its growth drivers.

Glaukos' (GKOS) Q1 Earnings Beat Estimates, Sales Rise Y/Y

Glaukos' (GKOS) Q1 revenues beat estimates but fall year over year. Sales and gross margin improve, while higher operating expenses lead to wider operating loss.

CVS Health (CVS) Q1 Earnings Surpass Estimates, EPS View Cut

CVS Health's (CVS) robust sales growth across all three operating segments drives top-line results.

PacBio (PACB) Tops on Q1 Earnings, Raises FY23 Revenue View

PacBio (PACB) witnesses strong revenue growth in the first quarter. This is partly aided by customers' product transition to the Revio system.

DENTSPLY SIRONA (XRAY) Q1 Earnings & Revenues Beat Estimates

DENTSPLY SIRONA's (XRAY) Q1 earnings and revenues decline year over year, driven by the unfavorable foreign currency movement and soft demand across all geographical segments.

Penumbra (PEN) Q1 Earnings Top Estimates, Sales Remain Robust

Penumbra's (PEN) sales during the first quarter reflect continued demand for its products. The 2023 outlook is encouraging as earnings improve despite macro challenges.